Scarica l'app Stockscreener
19.82
42.58%
-14.70
Dopo l'orario di chiusura:
20.00
0.18
+0.91%
Neurogene Inc Borsa (NGNE) Ultime notizie
Neurogene: Q3 Earnings Snapshot - San Antonio Express-News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc.NGNE - PR Newswire
Neurogene Inc reports results for the quarter ended September 30Earnings Summary - XM
Neurogene Inc (NGNE) Quarterly 10-Q Report - Quartz
Neurogene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Neurogene Reports Promising Rett Syndrome Trial Data Despite Wider Q3 Loss | NGNE Stock News - StockTitan
Stock Market News: QMMM Holdings plunges by 69% whereas Neurogene falls by 44.05% during mid day trading - Business Upturn
Bronstein, Gewirtz & Grossman, LLC Is Investigating Neurogene Inc. (NGNE) And Encourages Stockholders to Connect - AccessWire
Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Neurogene stock plunges 36% on NGN-401 study update (NASDAQ:NGNE) - Seeking Alpha
Neurogene falls again on Rett gene therapy side effects - pharmaphorum
Neurogene Drops High-Dose Cohort of Gene-Therapy Study for Rett Syndrome - MarketWatch
Neurogene Adjusts NGN-401 Trial After Adverse Event - TipRanks
Neurogene Halts High-Dose Rett Syndrome Trial After Critical Safety Event, FDA Clears Low Dose | NGNE Stock News - StockTitan
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Neurogene Inc. (NASDAQ:NGNE) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Neurogene To Report Rett Syndrome Trial Data Next WeekStock Up 90% In 8 Months - RTTNews
Janus Henderson Group PLC's Strategic Reduction in Neurogene Inc Holdings - GuruFocus.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.86% - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation - AccessWire
RTW INVESTMENTS, LP Expands Stake in Neurogene Inc - GuruFocus.com
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?" - MarketBeat
Neurogene (NASDAQ:NGNE) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Investors to Reach Out - AccessWire
Neurogene’s NGN-401 gene therapy scores well in Rett syndrome - The Pharma Letter
Top 1% Biotech Neurogene Crashes, Wiping Out A Run, On A Serious Side Effect - MSN
FMR LLC Expands Stake in Neurogene Inc - GuruFocus.com
Neurogene shares target lifted, outperform on positive data By Investing.com - Investing.com Australia
Neurogene stock target up as Stifel notes consistent efficacy despite emerging safety concerns - Investing.com Canada
Neurogene’s Rett Data Draw Optimism Despite Serious Adverse Event - Citeline
Neurogene Gene Therapy Shows Signs of Efficacy in Small Study, But an Adverse Event Spooks Investors - MedCity News
Neurogene stock target cut, reiterates outperform on trial results By Investing.com - Investing.com Canada
U.S. Stock market top losers: Neurogene Inc. declines by 46.04% while Pagaya Technologies falls by 34.87% during mid day trading - Business Upturn
U.S. Stock market: BTC Digital(+314.68%), BTCS Inc.(+35.64%), Neuronetics(−41.36%) among most volatile stocks during mid day trading - Business Upturn
Neurogene shares target lifted, outperform on positive data - Investing.com
Neurogene shares fall on Rett syndrome gene therapy data - pharmaphorum
Neurogene hits a setback in the clinic, days after fundraise - BioPharma Dive
Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial - Benzinga
Neurogene Reports Promising Interim Results for NGN-401 Trial - TipRanks
U.S. Stock market top losers: Pagaya Technologies drops by 31.44%, Rockwell Medical declines by26.24% in early trading - Business Upturn
Leerink Partners Forecasts Strong Price Appreciation for Neurogene (NASDAQ:NGNE) Stock - MarketBeat
U.S. Stock market most volatile stocks: Neuronetics(-47.27%), Heron Therapeutics(-20.15%) and LogicMark(+94.36%) in early trading - Business Upturn
Neurogene (NASDAQ:NGNE) Price Target Raised to $55.00 at HC Wainwright - MarketBeat
Robert W. Baird Increases Neurogene (NASDAQ:NGNE) Price Target to $72.00 - MarketBeat
Neurogene Shares Tank After Adverse Event Linked to Early-Stage Rett Syndrome Gene Therapy - BioSpace
Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Da - GuruFocus.com
Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Data - Yahoo Finance
Neurogene’s stock sinks after adverse event with Rett syndrome gene therapy - Clinical Trials Arena
Neurogene reports promising Rett syndrome trial data By Investing.com - Investing.com South Africa
Neurogene reports promising Rett syndrome trial data - Investing.com India
Neurogene plummets 35% on gene therapy trial data for Rett syndrome - Seeking Alpha
Neurogene's Rett Syndrome Gene Therapy Shows Breakthrough Results in Early Trial | NGNE Stock News - StockTitan
Neurogene (NASDAQ:NGNE) Hits New 52-Week HighShould You Buy? - MarketBeat
Neurogene: Interesting CNS Disease Company, Data Coming Soon (NASDAQ:NGNE) - Seeking Alpha
FY2024 EPS Estimates for Neurogene Increased by Analyst - Defense World
Neurogene FY2024 EPS Estimate Increased by Leerink Partnrs - MarketBeat
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - News & Insights
Neurogene (NASDAQ:NGNE) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Neurogene Secures $200M for Genetic Therapy Development - Yahoo Finance
Neurogene Announces Oversubscribed $200 Million Private Placement - BioSpace
Beam Therapeutics (BEAM) Stock Surges with Strong Trading Volume - GuruFocus.com
S&P 500 Edges Lower; Yum China Earnings Top Views - Benzinga
How Did the Markets React? A Day of Ups and Downs for U.S. Stocks! - Jomfruland.net
Neurogene Reaches 52-Week High on $200M Private Placement - MarketWatch
Crude Oil Gains 3%; Constellation Energy Shares Tumble After Q3 Results - Benzinga
U.S. stock market: Glatfelter soars 1,106.32%, Nuwellis jumps 114.71%, and Staffing 360 Solutions rises 72.94% in significant midday market gains - Business Upturn
Neurogene secures $200 million in oversubscribed PIPE financing By Investing.com - Investing.com South Africa
Neurogene secures $200M ahead of anticipated study readout - BioPharma Dive
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):